Evidence map›Paper›PMID 41028731›Full record

ArticleNature communications2025

Escherichia coli phylogeny drives co-amoxiclav resistance through variable expression of TEM-1 beta-lactamase.

William Matlock, Gillian Rodger, Emma Pritchard, Matthew Colpus, Natalia Kapel, Lucinda Barrett, Marcus Morgan, Sarah Oakley, Katie L Hopkins, Aysha Roohi and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

William Matlock *Department of Biology, University of Oxford, Oxford, UK. william.matlock@biology.ox.ac.uk.ORCID http://orcid.org/0000-0001-5608-0423
Gillian Rodger *Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Emma PritchardNuffield Department of Medicine, University of Oxford, Oxford, UK.
Matthew ColpusThe National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.ORCID http://orcid.org/0009-0008-2219-4084
Natalia KapelThe National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-5914-9999
Lucinda BarrettOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Marcus MorganOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Sarah OakleyOxford University Hospitals NHS Foundation Trust, Oxford, UK.
Katie L HopkinsUK Health Security Agency, Colindale, UK.
Aysha RoohiNuffield Department of Medicine, University of Oxford, Oxford, UK.
Drosos KarageorgopoulosOxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID http://orcid.org/0000-0002-9959-9978
Matthew B AvisonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.
A Sarah WalkerNuffield Department of Medicine, University of Oxford, Oxford, UK.
Samuel LipworthNuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-5872-9214
Nicole StoesserNuffield Department of Medicine, University of Oxford, Oxford, UK. nicole.stoesser@ndm.ox.ac.uk.ORCID http://orcid.org/0000-0002-4508-7969

Funding

DH | National Institute for Health Research (NIHR) NIHR200915Wellcome TrustWellcome Trust (Wellcome) 203141/Z/16/Z
6 · The paper itself

Abstract

Co-amoxiclav (amoxicillin and clavulanate) is a commonly used combination antibiotic, with resistance in Escherichia coli associated with increased mortality. The class A beta-lactamase bla

Indexed as

Anti-Bacterial Agentsbeta-LactamasesEscherichia coliBayes TheoremEscherichia coli InfectionsEscherichia coli ProteinsGene Expression Regulation, BacterialGenotypeHumansMicrobial Sensitivity TestsPhylogenyAnti-Bacterial Agentsbeta-Lactamasesbeta-lactamase TEM-1Escherichia coli Proteins

Identifiers

PMID41028731
PMCPMC12484619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.